JP2020503252A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020503252A5 JP2020503252A5 JP2019521034A JP2019521034A JP2020503252A5 JP 2020503252 A5 JP2020503252 A5 JP 2020503252A5 JP 2019521034 A JP2019521034 A JP 2019521034A JP 2019521034 A JP2019521034 A JP 2019521034A JP 2020503252 A5 JP2020503252 A5 JP 2020503252A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- clec
- composition according
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022025697A JP7404418B6 (ja) | 2016-10-21 | 2022-02-22 | Ｔ細胞応答を促進するための方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16306381 | 2016-10-21 | ||
| EP16306381.1 | 2016-10-21 | ||
| EP17305988 | 2017-07-24 | ||
| EP17305988.2 | 2017-07-24 | ||
| PCT/EP2017/076911 WO2018073440A1 (en) | 2016-10-21 | 2017-10-20 | Methods for promoting t cells response |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022025697A Division JP7404418B6 (ja) | 2016-10-21 | 2022-02-22 | Ｔ細胞応答を促進するための方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2020503252A JP2020503252A (ja) | 2020-01-30 |
| JP2020503252A5 true JP2020503252A5 (https=) | 2020-12-03 |
| JP7032396B2 JP7032396B2 (ja) | 2022-03-08 |
| JP7032396B6 JP7032396B6 (ja) | 2022-03-22 |
Family
ID=60293924
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019521034A Active JP7032396B6 (ja) | 2016-10-21 | 2017-10-20 | Ｔ細胞応答を促進するための方法 |
| JP2022025697A Active JP7404418B6 (ja) | 2016-10-21 | 2022-02-22 | Ｔ細胞応答を促進するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022025697A Active JP7404418B6 (ja) | 2016-10-21 | 2022-02-22 | Ｔ細胞応答を促進するための方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11365257B2 (https=) |
| EP (2) | EP3529262B1 (https=) |
| JP (2) | JP7032396B6 (https=) |
| KR (1) | KR102646708B1 (https=) |
| CN (1) | CN110291102A (https=) |
| AU (1) | AU2017345286B2 (https=) |
| CA (1) | CA3039348C (https=) |
| CY (1) | CY1124584T1 (https=) |
| DK (1) | DK3529262T3 (https=) |
| ES (2) | ES2883678T3 (https=) |
| HR (1) | HRP20211544T1 (https=) |
| HU (1) | HUE056016T2 (https=) |
| IL (1) | IL266111B (https=) |
| LT (1) | LT3529262T (https=) |
| MA (1) | MA46570B1 (https=) |
| MD (1) | MD3529262T2 (https=) |
| PL (1) | PL3529262T3 (https=) |
| RS (1) | RS62463B1 (https=) |
| SI (1) | SI3529262T1 (https=) |
| SM (1) | SMT202100555T1 (https=) |
| WO (1) | WO2018073440A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2883678T3 (es) * | 2016-10-21 | 2021-12-09 | Inst Nat Sante Rech Med | Métodos para promover la respuesta de linfocitos T |
| SG11201907870VA (en) | 2017-02-28 | 2019-09-27 | Vor Biopharma Inc | Compositions and methods for inhibition of lineage specific proteins |
| CA3110837A1 (en) | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| CN115151309A (zh) * | 2019-12-05 | 2022-10-04 | Ose免疫疗法 | 抗clec-1a抗体及其抗原结合片段 |
| CN113156140A (zh) * | 2021-03-05 | 2021-07-23 | 青岛大学附属医院 | C型凝集素样受体-1作为真菌性角膜炎的治疗标志物的应用 |
| WO2022258714A1 (en) | 2021-06-08 | 2022-12-15 | Ose Immunotherapeutics | Humanized anti-clec-1a antibodies and antigen-binding fragments thereof and mimetics thereof |
| WO2023083890A1 (en) * | 2021-11-09 | 2023-05-19 | Ose Immunotherapeutics | Identification of clec-1 ligand and uses thereof |
| US20260035434A1 (en) | 2022-08-01 | 2026-02-05 | Ose Immunotherapeutics | Heterodimeric fc-clec-1 fusion molecule and uses thereof |
| WO2025032213A1 (en) | 2023-08-10 | 2025-02-13 | Ose Immunotherapeutics | Identification of hla-dra as a ligand of clec-1 and uses thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| AU701578B2 (en) | 1992-08-21 | 1999-02-04 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| US5618829A (en) | 1993-01-28 | 1997-04-08 | Mitsubishi Chemical Corporation | Tyrosine kinase inhibitors and benzoylacrylamide derivatives |
| AU691820B2 (en) | 1993-07-15 | 1998-05-28 | Cancer Research Campaign Technology Limited | Prodrugs of protein tyrosine kinase inhibitors |
| EP0690452A3 (en) | 1994-06-28 | 1999-01-07 | Advanced Micro Devices, Inc. | Electrically erasable memory and method of erasure |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| US5639757A (en) | 1995-05-23 | 1997-06-17 | Pfizer Inc. | 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors |
| HU228446B1 (en) | 1996-04-12 | 2013-03-28 | Warner Lambert Co | Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| US6100254A (en) | 1997-10-10 | 2000-08-08 | Board Of Regents, The University Of Texas System | Inhibitors of protein tyrosine kinases |
| US6740665B1 (en) | 1999-02-10 | 2004-05-25 | Ramachandran Murali | Tyrosine kinase inhibitors and methods of using the same |
| US6245759B1 (en) | 1999-03-11 | 2001-06-12 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| AU5636900A (en) | 1999-06-30 | 2001-01-31 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| JP2003503351A (ja) | 1999-06-30 | 2003-01-28 | メルク エンド カムパニー インコーポレーテッド | Ｓｒｃキナーゼ阻害化合物 |
| WO2001000214A1 (en) | 1999-06-30 | 2001-01-04 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| DE60023926T2 (de) | 1999-09-10 | 2006-07-20 | Merck & Co., Inc. | Tyrosin kinase inhibitoren |
| US6794393B1 (en) | 1999-10-19 | 2004-09-21 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| AU778042B2 (en) | 1999-10-19 | 2004-11-11 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| HRP20020349A2 (en) | 1999-10-19 | 2004-02-29 | Merck & Co Inc | Tyrosine kinase inhibitors |
| AU785198B2 (en) * | 1999-11-15 | 2006-11-02 | Miltenyi Biotec B.V. & Co. KG | Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognised thereby and cells obtained thereby |
| US6313138B1 (en) | 2000-02-25 | 2001-11-06 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6420382B2 (en) | 2000-02-25 | 2002-07-16 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| ATE316088T1 (de) | 2001-06-22 | 2006-02-15 | Merck & Co Inc | Tyrosin-kinase inhibitoren |
| WO2003011836A1 (en) | 2001-08-01 | 2003-02-13 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| WO2003020276A1 (en) | 2001-08-30 | 2003-03-13 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US8246959B1 (en) * | 2003-08-01 | 2012-08-21 | University Of Washington | Dendritic cell-associated lectin-like molecules, compositions and methods of use |
| US7908091B2 (en) | 2006-03-17 | 2011-03-15 | Prometheus Laboratories Inc. | Methods of predicting and monitoring tyrosine kinase inhibitor therapy |
| US20080254047A1 (en) * | 2007-02-23 | 2008-10-16 | Baylor Research Institute | Activation of Human Antigen-Presenting Cells Through CLEC-6 |
| JP5641508B2 (ja) * | 2010-02-23 | 2014-12-17 | 国立大学法人 東京大学 | 樹状細胞免疫受容体刺激剤 |
| KR20170037625A (ko) * | 2014-07-21 | 2017-04-04 | 노파르티스 아게 | Cll-1 키메라 항원 수용체를 사용한 암의 치료 |
| ES2883678T3 (es) | 2016-10-21 | 2021-12-09 | Inst Nat Sante Rech Med | Métodos para promover la respuesta de linfocitos T |
-
2017
- 2017-10-20 ES ES17797066T patent/ES2883678T3/es active Active
- 2017-10-20 RS RS20211221A patent/RS62463B1/sr unknown
- 2017-10-20 KR KR1020197014209A patent/KR102646708B1/ko active Active
- 2017-10-20 MD MDE20190953T patent/MD3529262T2/ro unknown
- 2017-10-20 LT LTEPPCT/EP2017/076911T patent/LT3529262T/lt unknown
- 2017-10-20 CA CA3039348A patent/CA3039348C/en active Active
- 2017-10-20 DK DK17797066.2T patent/DK3529262T3/da active
- 2017-10-20 HU HUE17797066A patent/HUE056016T2/hu unknown
- 2017-10-20 HR HRP20211544TT patent/HRP20211544T1/hr unknown
- 2017-10-20 EP EP17797066.2A patent/EP3529262B1/en active Active
- 2017-10-20 ES ES21178847T patent/ES2978486T3/es active Active
- 2017-10-20 CN CN201780065072.6A patent/CN110291102A/zh active Pending
- 2017-10-20 JP JP2019521034A patent/JP7032396B6/ja active Active
- 2017-10-20 PL PL17797066T patent/PL3529262T3/pl unknown
- 2017-10-20 IL IL266111A patent/IL266111B/en unknown
- 2017-10-20 US US16/343,757 patent/US11365257B2/en active Active
- 2017-10-20 AU AU2017345286A patent/AU2017345286B2/en active Active
- 2017-10-20 SI SI201730876T patent/SI3529262T1/sl unknown
- 2017-10-20 EP EP21178847.6A patent/EP3950709B1/en active Active
- 2017-10-20 WO PCT/EP2017/076911 patent/WO2018073440A1/en not_active Ceased
- 2017-10-20 SM SM20210555T patent/SMT202100555T1/it unknown
- 2017-10-20 MA MA46570A patent/MA46570B1/fr unknown
-
2021
- 2021-09-24 CY CY20211100839T patent/CY1124584T1/el unknown
-
2022
- 2022-02-22 JP JP2022025697A patent/JP7404418B6/ja active Active
- 2022-05-10 US US17/740,849 patent/US12091464B2/en active Active
-
2024
- 2024-08-21 US US18/811,491 patent/US20240400695A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020503252A5 (https=) | ||
| Gandullo-Sánchez et al. | HER3 in cancer: from the bench to the bedside | |
| JP2022065159A5 (https=) | ||
| Fluharty et al. | An N-terminal fragment of the prion protein binds to amyloid-β oligomers and inhibits their neurotoxicity in vivo | |
| RU2492185C2 (ru) | Связывающие протеины, специфичные по отношению к инсулин-подобным факторам роста, и их использование | |
| ES2788868T3 (es) | Método para modular el apetito | |
| Lee et al. | Inhibition of breast cancer growth and metastasis by a biomimetic peptide | |
| CN103965363B (zh) | 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 | |
| Foy et al. | Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo | |
| JP2021119138A (ja) | 成長分化因子１５（ｇｄｆ−１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用 | |
| JP2020506727A5 (https=) | ||
| JP2014524746A5 (https=) | ||
| EA201391449A1 (ru) | Антитела против пептидов цитозоля | |
| JP2015529641A5 (https=) | ||
| JP2010163438A5 (https=) | ||
| RU2016135062A (ru) | Направленное ингибирование tgf бeta | |
| HRP20211544T1 (hr) | Postupci za unapređivanje odgovora t stanica | |
| Liu‐Chittenden et al. | Phase I trial of systemic intravenous infusion of interleukin‐13‐Pseudomonas exotoxin in patients with metastatic adrenocortical carcinoma | |
| Lu et al. | Novel human Ab against vascular endothelial growth factor receptor 2 shows therapeutic potential for leukemia and prostate cancer | |
| Choi et al. | Shed syndecan-2 enhances tumorigenic activities of colon cancer cells | |
| JP2020522512A5 (https=) | ||
| Lee et al. | Novel strategy for a bispecific antibody: induction of dual target internalization and degradation | |
| DK2984108T3 (en) | Anti-s100a7 antibodies for the treatment and diagnosis of cancer | |
| RU2015154985A (ru) | Способы лечения рака | |
| Wu et al. | Anti-metastatic effect of the TM4SF5-specific peptide vaccine and humanized monoclonal antibody on colon cancer in a mouse lung metastasis model |